Procopio et al., 2014 - Google Patents

Sorafenib as first-or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

Procopio et al., 2014

View PDF
Document ID
18024268221395044037
Author
Procopio G
Derosa L
Gernone A
Morelli F
Sava T
Zustovich F
De Giorgi U
Ferrari V
Sabbatini R
Gasparro D
Felici A
Burattini L
Calvani N
Lo Re G
Banna G
Pia Brizzi M
Rizzo M
Ciuffreda L
Iacovelli R
Ferrau F
Taibi E
Bracarda S
Porta C
Galligioni E
Contu A
Publication year
Publication venue
Future Oncology

External Links

Snippet

ABSTRACT Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first-or …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects

Similar Documents

Publication Publication Date Title
Marra et al. Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Nagasaka et al. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
Neal et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Iacovelli et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials
Solit et al. Towards a unified model of RAF inhibitor resistance
Gadaleta-Caldarola et al. Sorafenib: 10 years after the first pivotal trial
Jäger et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study
Liu et al. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
Di Lorenzo et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples
Inomata et al. Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer
Agwa et al. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
Abdel-Rahman et al. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis
Procopio et al. Sorafenib as first-or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
Garg et al. Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
Yuan et al. Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
Zeng et al. Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
Abdel-Rahman et al. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis
Vavalà Role of afatinib in the treatment of advanced lung squamous cell carcinoma
Procopio et al. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience
Areethamsirikul et al. The risk of secondary primary malignancies after therapy for multiple myeloma
Paglino et al. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study
Bersanelli et al. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
Antoun et al. Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma
Worley Lung cancer research is taking on new challenges: knowledge of tumors’ molecular diversity is opening new pathways to treatment
Abdel-Rahman et al. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis